Columbia University Medical Center, New York-Presbyterian and the Life Raft Group have entered into a collaborative effort to advance research to find a cure for GIST using a novel therapeutic approach and patient-driven data. [...]
Dr. Anthony Boral, Chief Medical Officer of Blueprint Medicines, provided an update on the clinical development of BLU-285, an investigational medicine being developed for patients with advanced GIST. The presentation included an [...]
"Aclarando Dudas" - Respestas de un especialista en GIST presentación del Dr. Matias Chacon, June 28, 2017.
The Life Raft Group presented an informative webcast on Fertility, Pregnancy and GIST. Presented on March 30, 2017 Learn about: Impact of cancer treatment on fertility Options to preserve eggs and sperm [...]
The Life Raft Group presented an informative webcast on Gene Fusions. Presented on February 22, 2017 Learn about: Recently identified gene fusions in GIST Populations they target Current studies that may identify them How they [...]
"GIST: La Vision Del Radiologo", presentación del Patricia Castillo MD, October 27, 2016.
On September 28, 2016, the Life Raft Group was pleased to have Melissa Simpson, Senior Program Manager in the Center for Benefits Access at the National Council on Aging share her knowledge and insight [...]
On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]
"GIST: Actualizacion en el tratamiento", presentación del Matias Chacon, May 12, 2016.
On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), originally for CML (Chronic Myeloid Leukemia), was approved by the FDA and became available for the first time in the United States through Sun Pharmaceuticals. In response to this transition, the LRG provided an educational Webinar to the CML and GIST communities on March 18th entitled “Generic Imatinib: Gaining Perspective.”